Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Appointed director
BIOCEPT INC (BIOC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/22/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Biocept Reports Second Quarter 2023 Financial Results SAN DIEGO—--Aug. 14, 2023— Biocept, Inc. , a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2023 and provides a business update. “Biocept's primary focus is establishing our proprietary cerebrospinal fluid assay CNSide ™ as standard of care. We continue to diligently work towards submission to the National Comprehensive Cancer Network ® for consideration to include CNSide in their standard-of-care guidelines. We believe securing this status will broaden physician adoption and support reimbursement that reflects our test's value in clinical decision-making,” said Antonino Morales, Biocept President and CEO. “Our ongoing FORESEE clinical trial i..."
05/16/2023 8-K Material Modifications to Rights of Security Holders, Financial Statements and Exhibits  Interactive Data
Docs: "Certificate of Amendment to Amended and Restated Certificate of Incorporation of Biocept, Inc",
"Certificate of Amendment to Amended and Restated Certificate of Incorporation of Biocept, Inc"
05/15/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Biocept Reports First Quarter 2023 Financial Results SAN DIEGO - Biocept, Inc. , a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2023 and provides a business update. “I'm exceptionally pleased with the progress being made with our FORESEE clinical trial, which is specifically designed to generate evidence of CNSide ™ 's clinical utility to support adoption into clinical care guidelines and further broaden physician use. Trial enrollment is running well in line with our plan, and we've now activated clinical sites in Dallas, Los Angeles and the San Francisco Bay Area,” said Samuel D. Riccitelli, Biocept's Chairman, and interim President and CEO. “In our quest to gain further physician and payor acceptan..."
04/17/2023 8-K Quarterly results
04/17/2023 8-K Quarterly results
03/20/2023 8-K Quarterly results
01/06/2023 8-K Results of Operations and Financial Condition, Cost Associated with Exit or Disposal Activities, Other Events, Financial Stat...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Biocept to Explore Strategic Alternatives and Implement Restructuring Plan SAN DIEGO - Biocept, Inc. today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has engaged EF Hutton, division of Benchmark Investments, Inc., as its financial advisor to assist in this process. Potential strategic alternatives that may be explored or evaluated as part of this process include an acquisition, merger, reverse merger, other business combination, sales of assets, licensing or other strategic transactions involving the company. There can be no assurance of a successful outcome from these efforts, or of the form or timing of any such outcome. The company does not intend to make any further disclosures regarding the strategic r..."
11/21/2022 8-K Quarterly results
11/18/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
10/19/2022 8-K Quarterly results
08/22/2022 8-K Quarterly results
07/14/2022 8-K Quarterly results
07/13/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
06/13/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
04/12/2022 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits  Interactive Data
Docs: "Letter from Mayer Hoffman McCann P.C. to the Securities and Exchange Commission",
"Letter from Mayer Hoffman McCann P.C. to the Securities and Exchange Commission"
04/07/2022 8-K Quarterly results
Docs: "Biocept Reports 2021 Fourth Quarter and Full Year Financial Results"
04/01/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Biocept Reports Unaudited 2021 Revenue and Year-End Cash Balance SAN DIEGO - Biocept, Inc . , a leading provider of molecular diagnostic assays, products and services, reports unaudited net revenue for 2021 of $61.2 million and cash and cash equivalents as of December 31, 2021 of approximately $28 million. “Revenue reached a record high in 2021, up 123% over the prior year driven primarily by RT-PCR COVID-19 testing. As anticipated, we are currently experiencing a decline in COVID-19 testing demand as the unpredictable pandemic begins shifting to an endemic stage. Also, in the fourth quarter of 2021 we once again achieved sequential-quarter volume growth for CNSide ™ , our proprietary cerebrospinal fluid assay for the detection and monitoring of cancer involving the central nervous system,..."
03/24/2022 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Second Amendment to Amended and Restated Bylaws of the Company",
"Second Amendment to Amended and Restated Bylaws of the Company"
03/08/2022 8-K Quarterly results
02/16/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Employment Offer Letter, by and between the Company and Samuel D. Riccitelli",
"Employment Offer Letter, by and between the Company and Antonino Morales"
01/31/2022 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review &nbsp...
11/22/2021 8-K Other Events  Interactive Data
08/16/2021 8-K Quarterly results
07/21/2021 8-K Submission of Matters to a Vote of Security Holders, Other Events  Interactive Data
07/20/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/15/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
05/12/2021 8-K Quarterly results
03/29/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Biocept Reports Third Quarter 2020 Financial Results Revenues of $6.6 million – a result of decision to offer COVID-19 testing Conference call begins at 4:30 p.m. Eastern time today"
10/21/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy